Literature DB >> 12676935

C-terminal amino acids of Helicobacter pylori alpha1,3/4 fucosyltransferases determine type I and type II transfer.

Bing Ma1, Ge Wang, Monica M Palcic, Bart Hazes, Diane E Taylor.   

Abstract

The alpha1,3/4 fucosyltransferase (FucT) enzyme from Helicobacter pylori catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc group of two series of acceptor substrates in H. pylori lipopolysaccharide: betaGal1,3betaGlcNAc (Type I) or betaGal1,4betaGlcNAc (Type II). Fucose is added either in alpha1,3 linkage of Type II acceptor to produce Lewis X or in alpha1,4 linkage of Type I acceptor to produce Lewis A, respectively. H. pylori FucTs from different strains have distinct Type I or Type II substrate specificities. FucT in H. pylori strain NCTC11639 has an exclusive alpha1,3 activity because it recognizes only Type II substrates, whereas FucT in H. pylori strain UA948 can utilize both Type II and Type I acceptors; thus it has both alpha1,3 and alpha1,4 activity, respectively. To identify elements conferring substrate specificity, 12 chimeric FucTs were constructed by domain swapping between 11639FucT and UA948FucT and characterized for their ability to transfer fucose to Type I and Type II acceptors. Our results indicate that the C-terminal region of H. pylori FucTs controls Type I and Type II acceptor specificity. In particular, the highly divergent C-terminal portion, seven amino acids DNPFIFC at positions 347-353 in 11639FucT, and the corresponding 10 amino acids CNDAHYSALH at positions 345-354 in UA948FucT, controls the Type I and Type II acceptor recognition. This is the opposite of mammalian FucTs where acceptor preference is determined primarily by the N-terminal residues in the hypervariable stem domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676935     DOI: 10.1074/jbc.M301704200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Helicobacter hepaticus Hh0072 gene encodes a novel alpha1-3-fucosyltransferase belonging to CAZy GT11 family.

Authors:  Lei Zhang; Kam Lau; Jiansong Cheng; Hai Yu; Yanhong Li; Go Sugiarto; Shengshu Huang; Li Ding; Vireak Thon; Peng G Wang; Xi Chen
Journal:  Glycobiology       Date:  2010-05-06       Impact factor: 4.313

2.  Membrane-associated activation of cholesterol α-glucosyltransferase, an enzyme responsible for biosynthesis of cholesteryl-α-D-glucopyranoside in Helicobacter pylori critical for its survival.

Authors:  Hitomi Hoshino; Akiko Tsuchida; Kiyokazu Kametani; Masako Mori; Tomoko Nishizawa; Takefumi Suzuki; Hitomi Nakamura; Heeseob Lee; Yuki Ito; Motohiro Kobayashi; Junya Masumoto; Masaya Fujita; Minoru Fukuda; Jun Nakayama
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

3.  Exploiting bacterial glycosylation machineries for the synthesis of a Lewis antigen-containing glycoprotein.

Authors:  Isabelle Hug; Blake Zheng; Bela Reiz; Randy M Whittal; Messele A Fentabil; John S Klassen; Mario F Feldman
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

4.  Fallacy of the Unique Genome: Sequence Diversity within Single Helicobacter pylori Strains.

Authors:  Jenny L Draper; Lori M Hansen; David L Bernick; Samar Abedrabbo; Jason G Underwood; Nguyet Kong; Bihua C Huang; Allison M Weis; Bart C Weimer; Arnoud H M van Vliet; Nader Pourmand; Jay V Solnick; Kevin Karplus; Karen M Ottemann
Journal:  mBio       Date:  2017-02-21       Impact factor: 7.867

5.  Quantum changes in Helicobacter pylori gene expression accompany host-adaptation.

Authors:  Eng-Guan Chua; Michael J Wise; Yalda Khosravi; Shih-Wee Seow; Arlaine A Amoyo; Sven Pettersson; Fanny Peters; Chin-Yen Tay; Timothy T Perkins; Mun-Fai Loke; Barry J Marshall; Jamuna Vadivelu
Journal:  DNA Res       Date:  2017-02-01       Impact factor: 4.458

6.  Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases.

Authors:  Christina Nilsson; Anna Skoglund; Anthony P Moran; Heidi Annuk; Lars Engstrand; Staffan Normark
Journal:  PLoS One       Date:  2008-11-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.